Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. James Richard Eshleman, MD PhD

James Richard Eshleman, MD PhD

Associate Director, Molecular Diagnostics Laboratory
Professor of Pathology

See Research on Pubmed

Male
Appointment Phone

410-955-3511

Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Associate Director, Molecular Diagnostics Laboratory
  • Professor of Pathology
  • Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Pathology

Research Interests

Colon cancer genetics; Genetic instability and mutation analysis; Molecular diagnosis of cancer

Biography

Dr. James Eshleman is a professor of pathology and oncology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include molecular diagnosis, transfusion medicine and residency training. Dr. Eshleman serves as the associate director of the Molecular Diagnostics Laboratory at the Johns Hopkins School of Medicine.

Dr. Eshleman earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine. He completed a residency in clinical pathology and a fellowship in blood banking and transfusion medicine at the Hospital of the University of Pennsylvania.

His research interests include colon cancer genetics, genetic instability and mutation analysis, and molecular diagnosis of cancer. His laboratory is involved in translational research in molecular diagnostics and basic science research on novel therapeutics.

Among his many accomplishments, Dr. Eshleman and his colleagues recently reported a novel method for point mutations detection and are using this method to help detect pancreatic cancer earlier. They also sequenced all genes for 24 pancreatic cancer samples and reported a new familial predisposition gene.

Languages

  • English
Additional Resources +
  • Education +

    Training

    • University of Pennsylvania Health System School of Medicine (Philadelphia PA) (1988)
    • University of Pennsylvania School of Medicine (Philadelphia PA) (1988)

    Residencies

    • Hospital of the University of Pennsylvania / Clinical Pathology (Philadelphia PA) (1992)

    Fellowships

    • Hospital of the University of Pennsylvania / Blood Banking/Transfusion Medicine (Philadelphia PA) (1993)

    Certifications

    • American Board of Pathology / Clinical Pathology (1992)
  • Research & Publications +

    Research Summary

    Dr. Eshleman's research program involves two major areas. The first is basic science of colon cancer, specifically the involvement of mutator phenotypes in colon carcinogenesis. Mutator phenotypes are increased mutation rates which commonly arise due to defects in DNA replication or repair. He and his lab are investigating the hypothesis that during carcinogenesis, cells acquire defects in DNA repair systems (e.g., mismatch repair) that profoundly increases their spontaneous mutation rate and their ability to deal with mutagens/carcinogens. These mutations then drive carcinogenesis and may play a role in evading therapy. It is also possible that cell defects in DNA repair can also be used therapeutically.

    The other area of Dr. Eshleman's research is translational research involving molecular diagnostics. The sequence of the human genome, knowledge of disease causing mutations, and molecular diagnostic tools are all significantly increasing. However, substantial gaps exist between basic science findings and the ability to apply them in the clinical setting.

    Selected Publications View all on PubMed

    1. Shi C, Fukushima N, Abe T, Bian Y, Hua L, Wendelburg BJ, Yeo CJ, Hruban RH, Goggins MG, and Eshleman JR. “Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection.” Cancer Biol Ther, 3/2008; 7:260-7.
    2. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, and Kinzler KW. “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.” Science. 9/2008; 321:1801-6.
    3. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, Anders RA, Goggins M, Hruban RH, and Eshleman JR. “KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: Implications for the human pancreatic cancer cell of origin.” Mol Cancer Res, 2/2009; 7:230-6 [NIHMS #89589].
    4. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Cheng-Ho Lin J, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigini G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, and Klein AP. “Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.” Science. 4/2009; 324:217.
    5. Shi C, Chandrasekharan A, Thuluvath PJ, Karikari C, Argani P, Goggins M, Maitra A, and Eshleman JR. “Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.” J Molec Diagnostics. 2009 Nov;11(6):583-9.

    Lab

    The Pathology Molecular Diagnostics Laboratory offers state-of-the-art clinical molecular testing for leukemia, lymphoma, solid tumors, cancer predisposition and a number of hematologic mutations associated with disease. Their tests are based on the latest research-based knowledge and provide initial diagnostic information, detection of residual disease following therapy, and assessment of disease risk for inherited conditions.

    The Pathology Cytogenetics Laboratory offers the most advanced clinical cytogenetics testing available for leukemia, lymphoma and solid tumors. The tests provide initial diagnostic information and minimal risidual disease detection following therapy or transplant. Expert results, interpretation and consultation services from these laboratories aid referring physicians, including oncologists, hematologists, pathologists, obstetricians and geneticists, in the appropriate diagnosis and management of their patients.

  • Academic Affiliations & Courses +

    Graduate Program Affiliation

    Pathobiology, Cellular and Molecular Medicine

  • Activities & Honors +
  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    The Johns Hopkins Hospital
    600 N. Wolfe Street
    David Koch Cancer Research Building-II Room Suite 344
    Baltimore, MD 21287
    Phone: 410-955-3511
    Appointment Phone: 410-955-3511
    Fax: 410-614-0671
    Location Map

    Department/Division

    • Pathology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer